Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

VK2735

VENTURE

Viking Therapeutics · Phase 2 · Completed · Enrollment 176

NCT06068946

The paper states the 2.5 mg and 15 mg ends of the weekly range, and the placebo result. It does not state each intermediate dose in the abstract cited here, so those registry arms stay n/r.

Y axis: Change in body weight from baseline, %

0-5-10-1504812162024VK2735 2.5 mg, week 13, -9.1%VK2735 2.5 mgVK2735 15 mg, week 13, -14.7%VK2735 15 mgPlacebo 13 weeks, week 13, -1.7%Placebo 13 weeks

X axis: Weeks since randomization

Cited trial source. Only weeks the source states.

  • VK2735 2.5 mg: week 13 -9.1%
  • VK2735 15 mg: week 13 -14.7%
  • Placebo 13 weeks: week 13 -1.7%

One reported week is a point at that week. It is not a line from 0%. A solid line connects two or more reported weeks.